REFERENCES


Choose an author or browse all
Choose the species or browse all
Choose a criteria for sorting
 Reverse sorting
Search for a protein
Search for a single PMID
Download references as CSV

Select O-GlcNAc references filter

Click to expand (2 results)

*Color correspond to species


Qiu S, Ma L, Yu K, Xu X, Zhang X, Yu W, Wang K, Tian X, Miao Y, Wang Y, Guo W, Xue X, Cui J, Yu X, Kang R, Zhou Q, Yu Y, Tang D, Wang J. A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. Developmental cell 2025 60(23) 40930100
Abstract:
Cytokines link inflammation to tumorigenesis, but the role of post-translational modifications in regulating their function within the extra-tumoral environment remains poorly defined. Here, we identify tumor-derived tumor necrosis factor (TNF) receptor superfamily member 11B (TR11B) as a key driver of lung adenocarcinoma (LUAD) progression and therapeutic resistance. Mechanistically, O-GlcNAc transferase (OGT)-mediated O-GlcNAcylation at serine 151 stabilizes TR11B and facilitates its interaction with the membrane protein EPS15 homology domain-containing protein 1 (EHD1), promoting cyclin dependent kinase 2 (CDK2) phosphorylation and cell cycle progression. Clinically, elevated O-GlcNAcylated TR11B correlates with advanced LUAD. Genetic deletion of Ogt suppresses tumor development in LUAD mouse models. Importantly, celecoxib, an U.S. Food and Drug Administration (FDA)-approved drug, inhibits O-GlcNAcylation and exerts antitumor effects. These findings reveal a pathological role for cytokine O-GlcNAcylation in LUAD and identify this axis as a potential therapeutic target.
O-GlcNAc proteins:
SMAP, TR11B, ARC1B, CREG1, STC2, KAD1, TPA, APOH, MT2, IL4, IPSP, RLA0, S10A9, G6PI, NPM, PSPB, FGF2, F16P1, LYAG, PCNA, CO6A1, ANXA3, RINI, CCL5, MIF, RSMB, PGCA, AT2A2, RL35A, MK, SFPQ, CPT2, RL13, EF1G, GRN, AMPL, RNAS4, RS19, AN32A, RL13A, RL27A, RL21, RL28, CAZA2, SEPP1, BCAM, TCPQ, TCP4, MFAP4, RS20, RL26, RS7, RS8, RS23, RS11, RUXE, SMD2, SMD3, RL7A, RS6, RS24, RS25, RS28, RS30, RL30, RL39, RL8, RS21, GSTO1, X3CL1, RL36A, SET, ODO1, CD47, PRDX4, POSTN, TEBP, NONO, SF3B4, PXDC2, SULF2, H2B3B, SMOC1, TBA4B, PDGFC, PSME2, MYH15, SF3B6, TIM13
Species: Homo sapiens
Download
Jiang K, Gao Y, Hou W, Tian F, Ying W, Li L, Bai B, Hou G, Wang PG, Zhang L. Proteomic analysis of O-GlcNAcylated proteins in invasive ductal breast carcinomas with and without lymph node metastasis. Amino acids 2016 48(2) 26374642
Abstract:
The potential role of protein O-GlcNAcylation in cancer has been studied extensively, and the spread of cancer cells to regional lymph nodes is the first step in the dissemination of breast cancer. However, the correlation between O-GlcNAcylation and lymphatic metastasis in breast cancer remains elusive. In this study, we demonstrated that the overall O-GlcNAcylation as well as O-GlcNAc transferase (OGT) tends to decrease in response to the augmentation of lymph node metastasis (LNM) in invasive ductal breast carcinomas (IDCs). Although accumulating evidence indicates that individual O-GlcNAcylation may be important in the pathogenesis of breast cancer, O-GlcNAcylated proteins in IDCs are still largely unexplored. Herein, O-GlcNAcylated proteins of IDCs were chemo-enzymatically enriched and identified via liquid chromatography combined with tandem mass spectrometry. In total, 155 O-GlcNAcylated proteins were determined, of which 41 were only observed in LNM tissues, while 40 were unique in non-LNM samples. Gene ontology analysis showed that O-GlcNAc is primarily a nucleocytoplasmic post-translational modification, and most enriched functional terms were related to cancer development in both metastatic and non-metastatic IDCs. Moreover, several O-GlcNAcylated proteins involved in glycolysis and its accessory pathway were identified from LNM and non-LNM groups, respectively. These results indicate that the O-GlcNAcylation statuses of individual proteins were independent of the overall O-GlcNAcylation levels of metastatic and non-metastatic IDCs. Aberrant O-GlcNAc modification of these proteins might be associated with LNM progression.
O-GlcNAc proteins:
IGLL5, NPT3, SURF4, OGT1, GGCT, LX12B, NCOR1, IDHC, AATM, ASSY, CYTA, PIGR, TRFL, CATA, VWF, G3P, HSPB1, ALDOB, ARGI1, ALDH2, S10A8, ATPB, S10A9, ENOA, PGK2, PDIA1, CATD, ANXA2, CAH3, GSTA2, GSTP1, F16P1, S31D3, UBC, THIO, CH60, HSP7C, LAMP1, ETFA, PLAK, DESP, HSP76, TGM1, LORI, ATPA, PSA5, PSB4, PSB6, GSTM2, TKT, SPB3, S10A7, CPSM, CASPE, S10AB, PRDX2, SPR1A, PGM1, TALDO, RL3, HUTH, SSRA, RS5, PSB2, CASP5, HMCS2, EPIPL, TPIS, IF4A1, RS3A, RS14, H4, RS24, 1433Z, ACTG, EF1A1, ACTS, HBB, ARF5, FABP5, DSG1, PRDX1, CKAP4, TGM3, DSC1, BLMH, DYHC1, DSC3, CDSN, SYPL1, HCDH, PTHD3, ACTBL, KPLCE, CNDH2, SBSN, DEN5B, FBX50, H32, H2AV, SPA24, HORN, KLD8B, POF1B, MUC16, TITIN, NAR4, BHMT1, MUCL1, DIRA2, SPB12, GSDMA, PSMD1, TCPH, PGES2, S10AE, ALG13, GNL3L, TBA8, ING1, NINL
Species: Homo sapiens
Download
Page 1 of 1